MobiHealth News February 14, 2024
Jessica Hagen

According to the bankruptcy petition, the company has liabilities of $1 billion to $10 billion with assets of $500 million to $1 billion.

Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business.

The San Francisco-based company is seeking approval from the U.S. Bankruptcy Court for the District of New Jersey to use its cash on hand to fund the case.

In its bankruptcy petition, the company listed assets of $500 million to $1 billion, but liabilities of $1 billion to $10 billion.

“We have been working diligently over the past eighteen months to improve...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Revolutionizing Primary Care: The Role of Pharmacogenomics and AI in Personalized Medicine
BioAro Announces Real Time DNA Decoding Technology
23andMe: What If …
23andMe CEO Anne Wojcicki considers taking company private
Age of Opportunity: Artificial Intelligence and the Precision Medicine Future

Share This Article